The Chemours Stock Forecast, Price & News

+0.32 (+0.97 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume1.92 million shs
Average Volume920,508 shs
Market Capitalization$5.50 billion
P/E Ratio21.73
Dividend Yield3.04%
30 days | 90 days | 365 days | Advanced Chart
Receive CC News and Ratings via Email

Sign-up to receive the latest news and ratings for The Chemours and its competitors with MarketBeat's FREE daily newsletter.

The Chemours logo

About The Chemours

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through four segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure and BaiMax brands for delivering whiteness, brightness, opacity, and protection in various of applications. The Thermal & Specialized Solutions segment offers of refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment provides polymers and advanced materials. Its Chemical Solutions segment offers industrial chemicals used in gold production, industrial, and consumer applications. The company sells its products through direct channels, as well as through a network of resellers and distributors. The Chemours Company was founded in 2014 and is headquartered in Wilmington, Delaware.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

3.15 out of 5 stars

Analyst Opinion: 3.4Community Rank: 4.3Dividend Strength: 2.5Insider Behavior: 2.5Valuation: 3.1 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

The Chemours (NYSE:CC) Frequently Asked Questions

Is The Chemours a buy right now?

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for The Chemours in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" The Chemours stock.
View analyst ratings for The Chemours
or view top-rated stocks.

What stocks does MarketBeat like better than The Chemours?

Wall Street analysts have given The Chemours a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The Chemours wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is The Chemours' next earnings date?

The Chemours is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for The Chemours

How were The Chemours' earnings last quarter?

The Chemours Company (NYSE:CC) released its earnings results on Thursday, July, 29th. The specialty chemicals company reported $1.20 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.89 by $0.31. The Chemours had a net margin of 4.57% and a trailing twelve-month return on equity of 63.22%.
View The Chemours' earnings history

How has The Chemours' stock been impacted by Coronavirus (COVID-19)?

The Chemours' stock was trading at $10.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CC shares have increased by 211.9% and is now trading at $33.25.
View which stocks have been most impacted by COVID-19

How often does The Chemours pay dividends? What is the dividend yield for The Chemours?

The Chemours declared a quarterly dividend on Wednesday, July 28th. Shareholders of record on Monday, August 16th will be paid a dividend of $0.25 per share on Wednesday, September 15th. This represents a $1.00 annualized dividend and a dividend yield of 3.01%. The ex-dividend date is Friday, August 13th.
View The Chemours' dividend history

Is The Chemours a good dividend stock?

The Chemours pays an annual dividend of $1.00 per share and currently has a dividend yield of 3.04%. The Chemours does not yet have a strong track record of dividend growth. The dividend payout ratio of The Chemours is 50.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, The Chemours will have a dividend payout ratio of 26.60% next year. This indicates that The Chemours will be able to sustain or increase its dividend.
View The Chemours' dividend history.

What guidance has The Chemours issued on next quarter's earnings?

The Chemours updated its FY 2021 earnings guidance on Thursday, July, 29th. The company provided earnings per share (EPS) guidance of $3.560-$3.560 for the period, compared to the Thomson Reuters consensus estimate of $3.560. The company issued revenue guidance of -.

What price target have analysts set for CC?

10 Wall Street analysts have issued 12-month price objectives for The Chemours' shares. Their forecasts range from $28.00 to $48.00. On average, they expect The Chemours' share price to reach $37.22 in the next twelve months. This suggests a possible upside of 11.9% from the stock's current price.
View analysts' price targets for The Chemours
or view top-rated stocks among Wall Street analysts.

Who are The Chemours' key executives?

The Chemours' management team includes the following people:
  • Mr. Sameer Ralhan, Sr. VP & CFO (Age 47, Pay $1.03M)
  • Mr. Mark E. Newman, COO, CEO, Pres & Director (Age 58, Pay $1.33M)
  • Mr. David C. Shelton Esq., Sr. VP, Gen. Counsel & Corp. Sec. (Age 57, Pay $868.15k)
  • Mr. Edwin C. Sparks, Pres of Titanium Technologies (Age 47, Pay $922.42k)
  • Mr. Matthew S. Abbott, VP, Chief Accounting Officer & Controller (Age 44)
  • Mr. Jonathan Lock, VP of Corp. Devel. & Investor Relations
  • Ms. Alvenia Scarborough, Sr. VP of Corp. Communications & Chief Brand Officer (Age 47)
  • Ms. Susan M. Kelliher, Sr. VP of People (Age 54)
  • Mr. E. Bryan Snell, Consultant (Age 64)
  • Ms. Alisha Bellezza, Pres of Thermal & Specialized Solutions (Age 45)

What is Mark Vergnano's approval rating as The Chemours' CEO?

106 employees have rated The Chemours CEO Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among The Chemours' employees.

Who are some of The Chemours' key competitors?

What other stocks do shareholders of The Chemours own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

What is The Chemours' stock symbol?

The Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Who are The Chemours' major shareholders?

The Chemours' stock is owned by a number of retail and institutional investors. Top institutional investors include Vaughan Nelson Investment Management L.P. (1.33%), Private Management Group Inc. (0.49%), Alliancebernstein L.P. (0.16%), Oregon Public Employees Retirement Fund (0.03%), New Mexico Educational Retirement Board (0.02%) and NEXT Financial Group Inc (0.01%). Company insiders that own The Chemours stock include Bradley J Bell, David C Shelton, E Bryan Snell, Edwin C Sparks, Mark Newman, Mark P Vergnano, Mary B Cranston, Matthew S Abbott and Richard H Brown.
View institutional ownership trends for The Chemours

Which major investors are selling The Chemours stock?

CC stock was sold by a variety of institutional investors in the last quarter, including Private Management Group Inc., Alliancebernstein L.P., and NEXT Financial Group Inc. Company insiders that have sold The Chemours company stock in the last year include Edwin C Sparks, Mark P Vergnano, and Matthew S Abbott.
View insider buying and selling activity for The Chemours
or view top insider-selling stocks.

Which major investors are buying The Chemours stock?

CC stock was bought by a variety of institutional investors in the last quarter, including Vaughan Nelson Investment Management L.P., Bristol John W & Co. Inc. NY, Raymond James Trust N.A., Brookstone Capital Management, New Mexico Educational Retirement Board, and Oregon Public Employees Retirement Fund. Company insiders that have bought The Chemours stock in the last two years include Bradley J Bell, David C Shelton, E Bryan Snell, Mark Newman, Mary B Cranston, and Richard H Brown.
View insider buying and selling activity for The Chemours
or or view top insider-buying stocks.

How do I buy shares of The Chemours?

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is The Chemours' stock price today?

One share of CC stock can currently be purchased for approximately $33.25.

How much money does The Chemours make?

The Chemours has a market capitalization of $5.50 billion and generates $4.97 billion in revenue each year. The specialty chemicals company earns $219 million in net income (profit) each year or $1.98 on an earnings per share basis.

How many employees does The Chemours have?

The Chemours employs 6,500 workers across the globe.

What is The Chemours' official website?

The official website for The Chemours is www.chemours.com.

Where are The Chemours' headquarters?

The Chemours is headquartered at 1007 MARKET STREET, WILMINGTON DE, 19801.

How can I contact The Chemours?

The Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at 302-773-1000 or via email at [email protected]

This page was last updated on 7/31/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.